Financial Daily from THE HINDU group of publications
Tuesday, Jan 25, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements


Korean FDA nod for Bharat Biotech's vaccine facility

Our Bureau

Hyderabad , Jan. 24

BHARAT Biotech International Ltd (BBIL), the Hyderabad-based pharma biotech company, has obtained the approvals from the Korean Food & Drugs Administration (FDA) for its human vaccines manufacturing facility located at Genome Valley near here.

Announcing this at a press conference here on Monday, the BBIL Chairman and Managing Director, Dr Krishna M. Ella, said the approval enables the company attain a level playing field and help reposition its entry into the global markets in the sphere of injectibles.

"Bharat Biotech can now manufacture and export human vaccines to Korea, which is one of the regulated markets in the world of pharmaceuticals," Dr Ella said. Other regulated markets include the US, Europe and Japan.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Phillips Carbon Black's eco protection


Ranbaxy makes 3 fresh ARV filings to WHO
Cox & Kings eyes hotel properties
Korean FDA nod for Bharat Biotech's vaccine facility
Dredging Corp plans interim dividend
Vybra Automet board okays pref offer
Lukewarm response to Actis' offer for Swaraj Mazda stake
Century Textiles to expand paper and denim units
Mangalore Chemicals to set up met coke unit — Shriram group taking 45 pc in new entity
Keltron staff on `relay strike'
ICRA signs pact with Turkish rating agency
Murugappa group offer to fishermen hit by tsunami
Bengal Immunity liquidation case deferred
Premier Auto unveils 2-tonner pick-up vehicle


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line